Mesa Laboratories, Inc.
MLABTechnologyNASDAQScientific & Technical Instruments · Last scanned Sep 9, 2026
Scan Results
Daily timeframePart of the technology sector, Mesa Laboratories, Inc. (MLAB) is listed under Scientific & Technical Instruments. At a $692.4M market cap, Mesa Laboratories, Inc. ranks as a small-cap company within technology. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
Market Cap
$692.4M
Beta
0.96
P/E (TTM)
147.31
P/E (Fwd)
12.05
EPS (TTM)
$0.84
EPS (Fwd)
$10.27
ROE
2.7%
ROA
3.3%
Cash
$32.2M
Total Debt
$161.4M
Free CF
$53.4M
52W Change
114.7%
Annual Financials
Cash vs Debt
Where MLAB stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, MLAB finished 32.73% above its 150-day moving average ($98.43) and 39.36% above its 200-day moving average ($93.75). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MLAB overbought or oversold?
At the September 3, 2026 close, MLAB's RSI(14) was 71.3, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Mesa Laboratories, Inc. carries $161.4M in total debt against $32.2M in cash reserves — debt is roughly 5.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $53.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 2.7%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.3% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $219.1M to $249.1M.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MLAB.